GlaxoSmithKline reports the results of clinical trials of its vaccine against bird flu, which has demonstrated that more than 80% of the subjects were protected by two shots, each containing only 3.8 micrograms of an antigen. This is a far better performance than the current vaccine on stockpile -- which is manufactured by Sanofi-Pasteur-- which demonstrated 50% protection after two doses of 90 micrograms each.

According to a New York Times article, GlaxoSmithKline will seek regulatory approval from the FDA this year, and if approved, the avian flu vaccine will sell for the same price as a standard flu shot, i.e., $8 to $12 a shot.

Read the full story here.